NCT02334553View on ClinicalTrials.gov

Single Dose Study to Evaluate the Safety, and Efficacy of S-1226 (8%) in Subjects With Mild Atopic Asthma

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 6, 2015

Primary Completion Date

November 25, 2015

Study Completion Date

November 25, 2015

Conditions
Asthma
Interventions
DRUG

S1226(8%)

The drug S1226(8%), consists of Perflubron (PFOB) and 8% CO2 delivered as an aerosol/vapour/gas mixture with a Circulaire nebulizer. The drug is administered as a single dose during the early phase asthmatic response for 2 minutes.

DRUG

Placebo

Normal saline nebulized with compressed medical air for 2 minutes during the early phase asthmatic response

Trial Locations (1)

T2N 4Z6

Respiratory Clinical Trials Centre, University of Calgary, Calgary

All Listed Sponsors
lead

SolAeroMed Inc.

INDUSTRY

NCT02334553 - Single Dose Study to Evaluate the Safety, and Efficacy of S-1226 (8%) in Subjects With Mild Atopic Asthma | Biotech Hunter | Biotech Hunter